Excalibur Fund Managers is a London, England based venture capital firm. They are focused solely on science and entrepreneurship in human medicines. Excalibur Fund Managers are investors, practictioners, scientists, adviser, enabler, facilitator and provider of medical and healthcare facilities.
Founded in 1996 by Sir Christopher Evans, Excalibur manages three funds, the Merlin Fund I, the Merlin Biosciences Fund, and MBF III. Across the three funds, they raised and managed a total of €450 million in 34 equity investments.
Investments
Excalibur Fund Managers has made investments in Ardana Bioscience, Neurotech, Plethora Solutions, Destination Skin, Cyclacel Pharmaceuticals, Takeda Cambridge, Intercytex Group, Onyvax, Microscience, Piramed, BioVex, Noxxon Pharma and ReNeuron Group.
They have exited their investments in ReNeuron Group, Noxxon Pharma, Cyclacel Pharmaceuticals, BioVex, Vectura, EpiCept Corporation, Arakis Limited, Energist, Plethora Solutions, Piramed and Microscience.
Timeline
Funded Companies
People
Beverley Borthwick
PA to Professor Sir Christopher Evans
Bill Edge
Board Member
Brenig Preest
Investment Director
Dr. Hellmut Krichner
Board Member
Jeremy Curnock Cook
Director
Martin Walton
Managing Director
Prof. Sir Chris Evans
Group Chairman
Professor Trevor Jones
Board Member
Shafia Zahoor
Finance Director
